Royalty Pharma (RPRX) Q2 2024 earnings summary

Executive summary

• Achieved 12% year-over-year growth in Portfolio Receipts and 11% in Royalty Receipts in Q2 2024, surpassing guidance and driven by a diversified portfolio of over 35 commercial products.

• Deployed over $2 billion in capital for new royalty transactions, including six new therapies and a $905 million investment in Voranigo following FDA approval.

• Raised full-year 2024 guidance for Portfolio Receipts to $2.7–$2.775 billion and Royalty Receipts growth to 9%–12%, reflecting strong performance and new investments.

• Maintained leadership in the biopharma royalty market, executing the majority of $500M+ transactions since IPO and holding a 77% market share in large deals.

• Portfolio includes royalties on 35+ commercial products and 16 development-stage candidates, with a focus on both direct and indirect funding of innovation.

Financial highlights

• Q2 2024 Portfolio Receipts grew 12% year-over-year to $608 million; Royalty Receipts were $605 million, up 11%.

• Adjusted EBITDA for Q2 was $574 million, with a margin of approximately 94%.

• Net income attributable to Royalty Pharma plc was $102 million for Q2 2024, down from $228 million in Q2 2023.

• Issued $1.5 billion in senior unsecured notes, increasing total debt to $7.8 billion at a weighted average cost of 3.1%.

• Cash and cash equivalents stood at $1.8 billion as of June 30, 2024.

Outlook and guidance

• Full-year 2024 Portfolio Receipts guidance raised to $2.7–$2.775 billion, with Royalty Receipts growth expected at 9%–12%.

• Milestones and other contractual receipts projected to decline from $600 million in 2023 to $30 million in 2024.

• Operating and professional costs expected at 8%–9% of Portfolio Receipts; interest paid forecasted at ~$160 million for 2024.

• Guidance excludes future royalty acquisitions and assumes negligible FX impact.

• No additional debt financing expected in 2024; 2025 interest paid projected at ~$260 million.